Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial.
Authors: Gough M R, Thibaud D, Smith R K W
Journal: Equine veterinary journal
Summary
# Editorial Summary: Tiludronate for Bone Spavin Treatment Bone spavin remains a significant cause of hindlimb lameness in horses, and whilst joint injections and farriery modifications form the foundation of management, pharmaceutical options that address the underlying pathophysiology are limited. Gough and colleagues investigated whether tiludronate—a bisphosphonate that inhibits osteoclast-mediated bone resorption—could ameliorate the abnormal bone remodelling characteristic of distal tarsal osteoarthritis. In their double-blind, placebo-controlled trial involving 108 horses with confirmed bone spavin, a single intravenous infusion of tiludronate (1 mg/kg) or placebo was administered alongside a controlled exercise programme, with lameness assessed via distal tarsal nerve blocks and radiography at baseline, 60 and 120 days. Tiludronate-treated horses showed significantly reduced lameness at Day 60 compared to placebo (P = 0.0318), with further improvement following a second infusion in initially non-responsive cases; notably, radiographic changes differed significantly only in the formation of periarticular osteophytes, suggesting clinical benefit may precede marked radiographic resolution. For practitioners managing bone spavin cases, particularly those with poor response to conventional therapies, tiludronate administered as part of a structured rehabilitation programme offers evidence-based medical intervention that targets pathological bone turnover rather than merely masking symptoms.
Read the full abstract on PubMed
Practical Takeaways
- •Tiludronate offers a medical alternative to farriery or surgical interventions for bone spavin, with measurable lameness improvement within 60 days when combined with controlled exercise
- •Single infusion at 1 mg/kg is the effective dose; consider a second treatment at 60 days for horses showing incomplete response
- •Best results require structured exercise management—this is not a standalone treatment but part of an integrated protocol
Key Findings
- •Tiludronate-treated horses were significantly less lame than placebo horses at 60 days (P = 0.0318)
- •Second tiludronate treatment at Day 60 showed further lameness improvement at Day 120 (P = 0.0096)
- •Tiludronate was associated with reduced periarticular osteophytes compared to placebo (P = 0.006)
- •87 of 108 horses completed the trial, demonstrating feasibility of single 1 mg/kg infusion protocol